Prelude Therapeutics Inc

8-K · prld-20260609.htm iXBRL

0001678660 2026-06-09 2026-06-09

 UNITED STATES
 SECURITIES AND EXCHANGE COMMISSION
 Washington, D.C. 20549
  
 FORM 8-K
  
 CURRENT REPORT
 Pursuant to Section 13 or 15(d)
 of the Securities Exchange Act of 1934
 Date of Report (Date of earliest event reported): June 9, 2026
  
 Prelude Therapeutics Incorporated
 (Exact Name of Registrant as Specified in its Charter)
  

  

  

  

  

  

 Delaware

  

 001-39527

  

 81-1384762

 (State or other jurisdiction of
incorporation or organization)

  

 (Commission
File Number)

  

 (I.R.S. Employer
Identification No.)

  

  

  

 175 Innovation Boulevard
 Wilmington , Delaware

  

 19805

 (Address of principal executive offices)

  

 (Zip Code)

 Registrant’s telephone number, including area code: (302) 467-1280
 Not Applicable
 (Former Name or Former Address, if Changed Since Last Report)
 Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 Securities registered pursuant to Section 12(b) of the Act:

  

  

  

  

  

 Title of each class

  

 Trading
Symbol(s)

  

 Name of each exchange on which registered

 Common Stock, $0.0001 par value per share

  

 PRLD

  

 Nasdaq Global Select Market

  
 Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company ☐
  
 If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

  
 Item 5.07 Submission of Matters to a Vote of Security Holders.
  
 On June 9, 2026, Prelude Therapeutics Incorporated (the "Company") held its 2026 Annual Meeting of Stockholders (the "Annual Meeting") and the following proposals were approved by the Company's stockholders:
 1. Election of three Class III Directors, Krishna Vaddi, Paul Scherer, and Katina Dorton, each to serve a three-year term, which will expire at the 2029 Annual Meeting of Stockholders and until such time as their respective successors have been duly elected and qualified or until such director’s earlier resignation or removal, based on the following votes:

  

 Nominees

 Shares For

 Shares Withheld

 Broker Non-Votes

 Krishna Vaddi, Ph.D.

  

 26,996,820

  

 55,937

  

 4,799,016

 Paul Scherer, MD, Ph.D.

  

 25,532,267

  

 1,520,490

  

 4,799,016

 Katina Dorton, J.D., MBA

  

 26,998,601

  

 54,156

  

 4,799,016

 2. Ratification of appointment of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026, based on the following votes:

  

 Shares For

 Shares Against

 Shares Abstaining

  

 Broker Non-Votes

 31,841,080

  

 4,951

  

 5,742

  

 0

 3. Advisory vote to approve the 2025 compensation for the Company's named executive officers, based on the following votes:

  

 Shares For

 Shares Against

 Shares Abstaining

  

 Broker Non-Votes

 26,869,142

  

 107,500

  

 76,115

  

 4,799,016

 4. Advisory vote on the frequency of advisory votes on the compensation for the Company's named executive officers, based on the following votes:

  

 1 Year

 2 Years

 3 Years

  

 Abstain

  

 Broker Non-Votes

 26,877,941

  

 65,638

  

 103,237

  

 5,941

  

 4,799,016

  
  
  
  

 SIGNATURE
 Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  

  

  

  

 PRELUDE THERAPEUTICS INCORPORATED
  
  

  

  

  

 Date: June 10, 2026

 By:

 / s/ Bryant Lim

  

  

 Bryant Lim

  

  

 Chief Legal Officer, Corporate Secretary, and Chief Financial Officer